Can IPG Photonics (IPGP) Trade At A Premium On Earnings?

IPG Photonics stock has declined by around 58.0% over the past five years, yet the shares still screen as expensive on the valuation checks that are available today.

• Over five years, IPG Photonics has fallen about 58.0%, which indicates that long term shareholders have faced a significant loss of value.
• The agreed €300 million acquisition of Lumibird Medical, with a potential €50 million earnout, can support expectations for a broader medical laser platform. However, integration and execution around this expansion may add uncertainty to future returns.
• IPG Photonics scores 2 out of 6 on Simply Wall St's broader valuation checks. This points to a stock that leans expensive rather than a clear bargain on standard metrics such as earnings and assets, see the full breakdown at 2/6 valuation checks.

The issue now is whether the current price for IPG Photonics already reflects the potential benefits of the Lumibird Medical deal, or if the long term share price decline still leaves room for an appealing entry point.

Find out why IPG Photonics' 17.5% return over the last year is lagging behind its peers.

Has IPG Photonics Run Too Far on Earnings?

The P/E ratio is a useful lens for IPG Photonics because the stock is being valued primarily on its earnings power rather than its assets. On this measure, IPG Photonics trades on a P/E of about 134.6x, which is more than four times the electronic industry average of 29.6x and well above the peer group average of 47.3x. That is a steep premium for a business that investors can already see has had a significant share price decline in recent years.

The Simply Wall St fair P/E ratio for IPG Photonics is 52.2x, based on factors such as its sector, risk profile and expected earnings characteristics. Compared with the current 134.6x, this indicates the stock is priced at a substantial premium to what this framework views as a more typical earnings multiple. Despite the planned Lumibird Medical acquisition, which aims to broaden the medical laser platform, the current P/E still suggests a rich valuation relative to these benchmarks.

On the P/E multiple, IPG Photonics stock appears expensive compared with both its tailored fair ratio and sector peers.

See what the numbers say about this price — find out in our valuation breakdown.

The IPG Photonics Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for IPG Photonics pick up where the valuation puzzle leaves off by spelling out which paths for IPG Photonics' future growth, margins and earnings would need to play out for the stock to be worth materially more or less than today's price, and they sit on the company's Community page. Rather than relying on a single multiple or model output, each narrative lays out the assumptions behind its fair value so you can compare them with actual results over time.

One of the top community narratives on IPG Photonics: 30% undervalued

"New growth initiatives in medical, semiconductor, and micromachining end-markets are gaining early traction, diversifying revenue streams and supporting higher margins over time as these higher-value verticals scale…"

Read one of the top narratives on IPG Photonics

Do you think there's more to the story for IPG Photonics? Head over to our Community to see what others are saying!

The Bottom Line

For IPG Photonics, the key issue is that the stock still screens as overvalued on earnings multiples, even after a substantial five year share price decline. The current P/E sits well above both sector averages and the tailored fair ratio. This implies that a lot of optimism is already embedded in the price.

From here, the crux of the debate is whether IPG Photonics can deliver the earnings and margin profile, including from the Lumibird Medical acquisition, that would eventually make this premium look justified rather than stretched.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com